Anti-neuroblastoma cell line antibodies in inflammatory demyelinating polyneuropathy: inhibition in vitro and in vivo by IV immunoglobulin.
We tested serum from 48 patients with Guillain-Barré syndrome and 42 with chronic inflammatory demyelinating polyneuropathy (CIDP) against a selected neuroblastoma cell line (NBL 108cc15). Forty-two percent of the patients showed a positive immunofluorescence test against the NBL 108cc15. These antibodies were mainly of the IgM-class; they disappeared in all seven CIDP patients retested after improvement following intravenous IgG treatment (IV-IgG) and were present in only 5% of serum from patients with other disorders. Absorption studies showed a partial homology between the NBL 108cc15 and human sciatic nerve. In vitro studies showed that IgG from pooled normal donors (IV-IgG) inhibits the reaction between serum from a CIDP patient and the NBL cell line. This inhibition may be due to neutralization of autoantibodies against nervous tissue by anti-idiotypic antibodies in IV-IgG.
van Doorn
P A
PA
Department of Neurology, Academic Hospital Dijkzigt, Rotterdam, The Netherlands.
Brand
A
A
Vermeulen
M
M
D000912:Antibodies, Neoplasm / Q000032:analysis* / Q000276:immunology; D002460:Cell Line; D003711:Demyelinating Diseases / Q000276:immunology* / Q000628:therapy; D005455:Fluorescent Antibody Technique; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis / Q000276:immunology / Q000627:therapeutic use; D007167:Immunotherapy; D007249:Inflammation / Q000276:immunology; D007275:Injections, Intravenous; D009447:Neuroblastoma; D010523:Peripheral Nervous System Diseases / Q000276:immunology* / Q000628:therapy
D000912:Antibodies, Neoplasm; D007074:Immunoglobulin G